Nov 17 (Reuters) – The US Food and Drug Administration’s drug evaluation department is proposing to withdraw approval for Salerno Pharmaceuticals’ liquid cholesterol medication, a Federal Register notice showed on Tuesday.
Here are more details:
• The basis for the proposal is that Salerno has repeatedly failed to file required annual reports for the drug FloLipid, and has not responded to the agency’s request for submission of the reports, the notice said
• Companies with an approved drug for human use are required to submit annual reports to FDA concerning their approved new drug application
• The company will be provided an opportunity for a hearing to show why the approval for the drug should not be withdrawn
• FloLipid, a blood cholesterol lowering medication, has been formulated to provide an effective liquid-form alternative for those who have difficulty swallowing pills
(Reporting by Sneha S K in Bengaluru; Editing by Shailesh Kuber)

